Equity · Healthcare
Twist Bioscience Corporation (TWST) perpetual futures
TWST perpetual futures on 16 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade TWSTUSDT.
Twist Bioscience is a synthetic biology company that sells synthetic genes, antibody libraries, sample-preparation tools and DNA-based data storage products, and collaborates with pharma and genomics partners.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
16/16 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
16 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KuCoin | Trade | TWST/USDT | Trading | $105.78 | 0.0% APR 0.000% every 8h | +25.5 bps | $2.9K | $207.2K | $3.4K | USDT | 20x | |
MEXC | Trade | TWST/USDT | Trading | $105.78 | 0.0% APR 0.000% every 8h | +4.7 bps | $43.4K | $101.8K | $1.5M | USDT | 20x | |
Bitunix | Trade | TWST/USDT | Trading | $105.80 | -6.2% APR -0.00567% every 8h | +0.9 bps | $100.4K | $70.7K | $44.7K | USDT | 20x | |
BingX | Trade | TWST-USDT | Trading | $105.80 | +5.5% APR +0.00500% every 8h | +2.8 bps | $32.9K | $37.2K | $307.6 | USDT | - | |
HTX | Trade | TWST/USDT | Trading | $105.81 | 0.0% APR 0.000% every 8h | +86.0 bps | $163K | $34.6K | $7.5K | USDT | - | |
XT.com | Trade | TWST/USDT | Trading | $105.81 | +11.0% APR +0.010% every 8h | +17.0 bps | $15K | $33K | - | USDT | 20x | |
Binance | Trade | TWST/USDT | Trading | $105.81 | 0.0% APR 0.000% every 8h | +1.9 bps | $28.1K | $32.6K | $109.8K | USDT | - | |
Bitget | Trade | TWST/USDT | Trading | $105.77 | 0.0% APR 0.000% every 8h | +5.7 bps | $209.5K | $30.7K | $87.2K | USDT | 20x | |
OKX | Trade | TWST/USDT | Trading | $105.85 | 0.0% APR 0.000% every 8h | +35.0 bps | $4.7K | $8K | $31.3K | USDT | 20x | |
BloFin | Trade | TWST/USDT | Trading | $105.81 | +2.6% APR +0.00240% every 8h | +2.8 bps | $24.6K | $7.4K | $6.6K | USDT | 20x | |
Bybit | Trade | TWST/USDT | Trading | $105.68 | 0.0% APR 0.000% every 8h | +24.6 bps | $5.8K | $4K | $53K | USDT | 25x | |
Hyperliquid HIP-3 | Trade | xyz:TWST | Trading | $105.35 | +194.5% APR +0.022% every 1h | +13.3 bps | $13K | $3.4K | $78.9K | USDC | 10x | |
Gate.io | Trade | TWST/USDT | Trading | $105.77 | 0.0% APR 0.000% every 8h | +129.8 bps | $6.7K | $542 | $14.8K | USDT | 20x | |
Crypto.com Exchange | Trade | TWST/USD | Trading | $105.51 | +5.0% APR +0.00057% every 1h | +10.4 bps | $2.6K | $0 | $668.9 | USD | 50x | |
LBank | Trade | TWST/USDT | Trading | $105.80 | 0.0% APR 0.000% every 8h | +18.9 bps | $1.8M | $647.8K | - | USDT | 50x | |
Ourbit | Trade | TWST/USDT | Trading | $105.80 | 0.0% APR 0.000% every 8h | +18.9 bps | $37.1K | $1.7M⚠ | $115K | USDT | 20x |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 12 of 16 venues absorb $10k · Typical cost: +24.3 bps – +54.2 bps
Cheapest execution: LBank · +7.9 bps
Too thin: Bybit, OKX, KuCoin, Crypto.com Exchange
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
TWSTTightest spread
TWSTHighest volume
TWSTFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $144.91 |
| 12-month target range (low – high) | $89 – $215 |
| Ratings in the provider's consensus | 15 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 2 | 7 | 4 | 1 | 0 |
| Oct 2026 | 2 | 7 | 3 | 1 | 0 |
| Sep 2026 | 2 | 7 | 3 | 1 | 0 |
| Aug 2026 | 2 | 7 | 2 | 0 | 0 |
| Jul 2026 | 2 | 8 | 2 | 0 | 0 |
| Jun 2026 | 2 | 8 | 1 | 0 | 0 |
| May 2026 | 1 | 8 | 2 | 0 | 0 |
| Apr 2026 | 1 | 7 | 2 | 0 | 0 |
| Mar 2026 | 1 | 7 | 2 | 0 | 0 |
| Feb 2026 | 1 | 7 | 2 | 0 | 0 |
| Jan 2026 | 1 | 7 | 2 | 0 | 0 |
| Dec 2025 | 1 | 7 | 2 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
TWST-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Twist Bioscience officer Cho Dennis received 7,045 common shares as a grant and sold 5,427 shares at $103.688 on 2026-11-16, leaving 80,238 shares owned.
Twist Bioscience officer Finn Patrick John was awarded 18,206 common shares and sold 12,752 shares at $103.688 on 2026-11-16, leaving 221,161 shares owned.
Twist Bioscience officer Paula Green was awarded 6,372 common shares and sold 4,281 shares at $103.688 on 2026-11-16, leaving 121,773 shares owned.
Twist Bioscience CEO Emily Leproust was granted 36,413 common shares as compensation and sold 19,045 shares at $103.688 on 2026-11-16, leaving 634,493 shares owned.
Twist Bioscience CAO Robert F. Werner received a 3,641-share Common Stock award and sold 1,637 shares at $103.688, leaving 49,571 shares held.
CFO Laponis Adam received a 7,828-share Common Stock award and sold 6,359 shares at $103.688 on 2026-11-16, leaving 118,501 shares owned.
CFO Adam Laponis received an award of 26,746 common shares of Twist Bioscience on 2026-11-12 at $0.00, a grant rather than a purchase, raising his holdings to 124,860 shares.
Green Paula (SVP of Human Resources) reported a sale of 20,429 shares of Twist Bioscience common stock on 2026-11-12, leaving 126,054 shares owned.
Twist Bioscience CAO Robert F. Werner was granted 8,439 shares of common stock on 2026-11-12, an award under code A, bringing his holdings to 51,208 shares.
Officer Dennis Cho sold 949 shares of Twist Bioscience common stock at $135.402 on Nov 3, 2026, leaving 62,840 shares held.
Twist Bioscience officer Finn Patrick John (President and COO) sold 2,565 shares of common stock on the open market at $135.402 on Nov 3, 2026, leaving 180,278 shares owned.
Twist Bioscience CEO Emily Leproust sold 4,573 common shares at $135.402 on Nov 3, 2026, leaving 558,187 shares owned.
Twist Bioscience officer Werner Robert F. sold 148 common shares in one open-market transaction at $135.402, leaving 42,769 shares owned.
Twist Bioscience officer Paula Green sold 1,007 common shares at $135.402 on Nov 3, 2026, leaving 105,625 shares owned.
Twist Bioscience officer Finn Patrick John (President and COO) sold 2,245 common shares on the open market at $134.589 on 2026-10-23, leaving 182,843 shares owned.
Twist Bioscience CFO Adam Laponis sold 2,462 common shares at $156.3049 on Oct 9, 2026, leaving 98,114 shares owned.
CEO Emily M. Leproust sold 3,338 common shares in three open-market transactions at $200.44-$202.32, leaving 563,970 shares owned.
Filings
79 · Latest SEC filingsTwist Bioscience officer Cho Dennis received 7,045 common shares as a grant and sold 5,427 shares at $103.688 on 2026-11-16, leaving 80,238 shares owned.
Twist Bioscience officer Finn Patrick John was awarded 18,206 common shares and sold 12,752 shares at $103.688 on 2026-11-16, leaving 221,161 shares owned.
Twist Bioscience officer Paula Green was awarded 6,372 common shares and sold 4,281 shares at $103.688 on 2026-11-16, leaving 121,773 shares owned.
Twist Bioscience CAO Robert F. Werner received a 3,641-share Common Stock award and sold 1,637 shares at $103.688, leaving 49,571 shares held.
CFO Laponis Adam received a 7,828-share Common Stock award and sold 6,359 shares at $103.688 on 2026-11-16, leaving 118,501 shares owned.
Twist Bioscience CEO Emily Leproust was granted 36,413 common shares as compensation and sold 19,045 shares at $103.688 on 2026-11-16, leaving 634,493 shares owned.
CFO Adam Laponis received an award of 26,746 common shares of Twist Bioscience on 2026-11-12 at $0.00, a grant rather than a purchase, raising his holdings to 124,860 shares.
Green Paula (SVP of Human Resources) reported a sale of 20,429 shares of Twist Bioscience common stock on 2026-11-12, leaving 126,054 shares owned.
Twist Bioscience CAO Robert F. Werner was granted 8,439 shares of common stock on 2026-11-12, an award under code A, bringing his holdings to 51,208 shares.
Twist Bioscience officer Finn Patrick John (President and COO) sold 2,565 shares of common stock on the open market at $135.402 on Nov 3, 2026, leaving 180,278 shares owned.
Twist Bioscience officer Paula Green sold 1,007 common shares at $135.402 on Nov 3, 2026, leaving 105,625 shares owned.
Twist Bioscience officer Werner Robert F. sold 148 common shares in one open-market transaction at $135.402, leaving 42,769 shares owned.
Officer Dennis Cho sold 949 shares of Twist Bioscience common stock at $135.402 on Nov 3, 2026, leaving 62,840 shares held.
Twist Bioscience CEO Emily Leproust sold 4,573 common shares at $135.402 on Nov 3, 2026, leaving 558,187 shares owned.
Twist Bioscience officer Finn Patrick John (President and COO) sold 2,245 common shares on the open market at $134.589 on 2026-10-23, leaving 182,843 shares owned.
Twist Bioscience CFO Adam Laponis sold 2,462 common shares at $156.3049 on Oct 9, 2026, leaving 98,114 shares owned.
CEO Emily M. Leproust sold 3,338 common shares in three open-market transactions at $200.44-$202.32, leaving 563,970 shares owned.
Officer Cho Dennis sold 9,514 shares of Twist Bioscience common stock (S-Sale) at $188.884 per share, leaving 63,789 shares owned.
Twist Bioscience officer Robert F. Werner sold 1,482 shares of Common Stock at $188.884 on Oct 2, 2026, leaving 42,917 shares owned.
Twist Bioscience CFO Adam Laponis sold 8,057 common shares (S-Sale) at $188.884 on 2026-10-02, leaving 100,576 shares.
Twist Bioscience officer Paula Green sold 10,088 common shares at $188.884 each, leaving 106,632 shares owned.
Twist Bioscience CEO Emily M. Leproust sold 46,391 common shares in two open-market sales on Oct 1-2, 2026, at prices from $188.884 to $200. She held 567,308 shares after the sales.
Twist Bioscience officer Finn Patrick John (President and COO) sold 25,714 common shares at $188.884 on Oct 2, 2026, leaving 185,088 shares owned.
CEO Emily Leproust sold 5,203 common shares in 10 open-market sales on 2026-09-24 at $175.23–$184.60, leaving 613,699 shares owned.
Twist Bioscience CEO Emily M. Leproust sold 1,687 common shares at $165.491 on Sept 21, 2026, leaving 618,902 shares held directly.
Twist Bioscience officer Paula Green (SVP of Human Resources) sold 294 common shares at $165.491 on 2026-09-21, leaving 116,720 shares owned.
Twist Bioscience officer Cho Dennis sold 348 common shares at $165.491 on 2026-09-21, leaving 73,303 shares owned.
CEO Emily Leproust exercised 208,708 options (M-Exempt) and sold 356,546 common shares at $151.46-$163.39 on 2026-09-17.
Twist Bioscience officer Cho Dennis sold 412 common shares at $122.624 on Sep 8, 2026, leaving 73,651 shares directly owned.
Twist Bioscience CEO Emily Leproust sold 2,302 common shares at $122.62 on Sept 8, 2026, leaving 768,427 shares owned.
Twist Bioscience officer Robert F. Werner (Chief Accounting Officer) reported selling 238 common shares at $122.624 on 2026-09-08, leaving 44,399 shares owned.
Twist Bioscience officer Paula Green (SVP of Human Resources) sold 907 common shares at $122.62 on Sept 8, 2026, leaving 117,014 shares owned.
CEO Emily M. Leproust sold 41,570 Twist Bioscience common shares in 5 open-market sales on 2026-08-25 at $150.564–$154.446, leaving 770,729 shares owned.
Officer Dennis Cho sold 1,598 shares of Twist Bioscience common stock at $139.07 each on August 21, 2026, leaving 74,063 shares owned.
President and COO Finn Patrick John sold 4,046 common shares of Twist Bioscience at $139.066 each on 2026-08-21, reducing his holdings to 210,802 shares.
Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,360 common shares at $139.066 each in an open-market transaction on 2026-08-21, leaving 117,921 shares owned.
CFO Laponis Adam sold 1,965 common shares of Twist Bioscience at $139.066 each on August 21, 2026.
On August 21, 2026, CEO Emily M. Leproust sold 6,639 common shares of Twist Bioscience at $139.066 each, holding 812,299 shares afterward.
Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold a total of 1,523 common shares in two open-market transactions on Aug 21 and Aug 24, 2026, at prices between $139.066 and $140.773. After the sales, his direct ownership decreased to 44,637 shares.
Dennis Cho, an officer of Twist Bioscience, sold 14,205 common shares at $129.75 each on August 19, 2026, leaving 75,661 shares owned.
Twist Bioscience officer Finn Patrick John exercised 23,355 stock options at $67.85 and sold 78,355 common shares in 7 open-market sales at $115.90–$122.58 on 2026-08-18. He held 214,678 shares after.
Katryn Blake, director, sold 2,240 common shares at $122.88 each on August 12, 2026, leaving 17,208 shares owned.
CEO Emily M. Leproust exercised 19,952 stock options at $26.66 and sold the same 19,952 common shares at $125.0756, leaving 818,938 shares owned.
CEO Leproust exercised options for 113,318 shares and immediately sold them at $125.1615 per share.
Twist Bioscience director Robert Chess exercised options on 18,417 shares at $11.89 and sold the same 18,417 shares on the open market at $110.89, leaving 21,084 shares owned.
On August 5, 2026, officer Dennis Cho sold 14,205 common shares of TWST at $109.75 each, reducing his holdings to 89,866 shares.
Dennis Cho, an officer of Twist Bioscience, sold 1,070 shares of common stock on August 3, 2026, at $85.3212 per share, retaining 104,071 shares.
CEO Emily Leproust sold 5,101 common shares of Twist Bioscience at $85.32 each on August 3, 2026, leaving 818,938 shares owned.
On Aug 3, 2026, SVP Paula Green sold 1,133 common shares of Twist Bioscience at $85.32 per share, reducing her holdings to 119,281.
President and COO Patrick John Finn sold 2,888 shares of Twist Bioscience common stock at $85.32 per share on August 3, 2026, leaving 269,678 shares owned.
On August 3, 2026, Chief Accounting Officer Robert F. Werner sold 167 common shares at $85.32 each, retaining 46,160 shares.
President and COO Patrick John Finn sold 2,238 common shares at $93.89 each on July 23, 2026, leaving 272,566 shares owned.
On July 9, 2026, CFO Adam Laponis sold 2,399 common shares at $94.334 each, leaving 110,276 shares owned.
CEO Emily Leproust sold 18,880 common shares at $95 each on 2026-06-25, retaining 824,039 shares.
Dennis Cho, an officer of Twist Bioscience, sold 14,205 common shares at $89.75 per share on June 24, 2026, retaining 105,141 shares.
On June 22, 2026, SVP of HR Paula Green sold 291 common shares at $87.32, reducing her holdings to 120,414 shares.
Cho Dennis sold 346 common shares at $87.32 each on June 22, 2026, leaving 119,346 shares owned.
Transcripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 21, 2026, 07:45 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Emily Marine Leproust
- Employees
- 979
- IPO date
- Oct 31, 2018
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 1/5
- Return on assetsi
- 1/5
- Debt to equityi
- 3/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Congressional disclosures
Market cap history
Not comparable with the headline: the provider's history counts about 62.62M shares, the headline 68.18M. Shown as the provider reports it.
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.02% | 2.1M |
| IWM | 0.34% | 1.7M |
| VB | 0.16% | 1.5M |
| NJM | 0.13% | 1.4M |
| ARKK | 3.33% | 1.3M |
| XBI | 1.98% | 1.3M |
| ARKG | 8.25% | 1.2M |
| VBK | 0.37% | 830.7K |
| FBGKX | 0.11% | 779.6K |
| VXF | 0.15% | 746.6K |
| VEXPX | 0.64% | 734.5K |
| FSSNX | 0.29% | 650.2K |
Analyst track record
How the analysts covering TWST have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 56 | 154 |
| Analysts | 13 | 18 |
| Buy / hold / sell | 49 / 5 / 2 | 128 / 17 / 9 |
| Upgrades / downgrades / initiations | 1 / 1 / 6 | 1 / 1 / 10 |
| Price targets hit / missed | 28 / 22 (56%) | 122 / 22 (85%) |
| Avg. return after a rating (TipRanks) | +41.2% | +116.6% |
| Best / worst call | +186.2% / -48.1% | +346.5% / -48.1% |
After buy calls on this stock: median 21-day move +4.6% vs S&P 500 +3.7% (n = 126)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Catherine Ramsey SchulteRobert W. Baird95% hit rate on this stock · 21 targets measuredBuytarget $135Nov 13, 2026
- Luke SergottBarclays76% hit rate on this stock · 17 targets measuredBuytarget $130Nov 13, 2026
- Brendan SmithTD Cowen50% hit rate on this stock · 12 targets measuredBuytarget $137Nov 13, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 13, 2026 | Puneet SoudaLeerink PartnersNov 13, 2026 | BuyReiterated | $175↗ | article ↗ |
| Nov 13, 2026 | Brendan SmithTD CowenNov 13, 2026 | BuyReiterated | $137↗ | article ↗ |
| Nov 13, 2026 | Catherine Ramsey SchulteRobert W. BairdNov 13, 2026 | BuyMaintained | $135↗ | article ↗ |
| Nov 13, 2026 | Luke SergottBarclaysNov 13, 2026 | BuyMaintained | $130↗ | article ↗ |
| Nov 13, 2026 | Doug SchenkelUBSNov 13, 2026 | HoldMaintained | $120↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 56 ratings
Frequently asked questions
Where can I trade TWST perpetual futures?
Twist Bioscience Corporation (TWST) perpetual futures trade on 16 crypto venues, including Ourbit, LBank, KuCoin. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade TWST around the clock?
Yes. Unlike the underlying stock, TWST perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on TWST perpetuals?
Right now the TWST perp funding rate is 0.0% annualized (venue median), ranging from -6.2% to +194.5% across 16 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the TWST perp price compare to the Twist Bioscience Corporation stock?
The venue-median TWST perp mark is $105.8 versus a reference stock price of $105.8, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a TWST perpetual future?
A TWST perpetual is a derivative that tracks the price of Twist Bioscience Corporation with no expiry date. It lets you take long or short exposure to Twist Bioscience Corporation on crypto venues, around the clock.
What is TWSTUSDT perpetual?
TWSTUSDT is the symbol most crypto exchanges use for the Twist Bioscience Corporation perpetual settled in USDT (Tether). It tracks the TWST share price through an index, trades 24/7 with leverage and never expires.
KuCoin
MEXC
Bitunix
BingX
HTX
XT.com
Binance
Bitget
OKX
BloFin
Bybit
Hyperliquid HIP-3
Gate.io
Crypto.com Exchange
LBank
Ourbit